glp 1 agonist binge eating disorder GLP-1 Drugs and Disorders: A Hidden Risk in the Weight Loss Revolution – The Chicago Council on Science and Technology GLP-1 receptor agonists are proving

Subrahmanyan NA, Koshy RM, Jacob K, Pappachan JM (2021) Efficacy and cardiovascular safety of DPP-4 inhibitors

Advertisement Large retrospective analysis may prompt prospective studies How to talk about lifetime risk, treatment goals, Lp(a) testing, statin skepticism and more Robust signal from observational study raises prospect of a long-sought medical therapy Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors Study is first to show reduction in autoimmune disease with the common diabetes and obesity drugs Surgical intervention linked to increased lifespan and reduced complications

Subgroup analyses (duration) of the effects of GLP-1 receptor agonists on the risk of overall respiratory disease

Multi-indication label expansion: Semaglutide approved across obesity, cardiovascular risk reduction, MASH, and sleep apnea creates a total addressable patient population of approximately 640 million globally nearly four times the obesity-only base adding new prescriber populations including cardiologists, hepatologists, and sleep medicine specialists

[DOI] [PMC free article] [PubMed] [Google Scholar] 57.Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., Halpern A., Krempf M., Lau D.C., le Roux C.W., Violante Ortiz R., Jensen C.B., et al

[36], in a real-world cohort treated with GLP-1 RAs including exenatide, observed a mean BW loss of 2.5 kg and a BMI reduction of 0.9 kg/m without a significant change in intrahepatic lipid content, reflecting variability in hepatic responses across populations